{
  "symbol": "PODD",
  "name": "Insulet Corporation",
  "sector": "Health Care",
  "industry": "Health Care Equipment",
  "date_added": "2023-03-15",
  "headquarters": "Acton, Massachusetts",
  "founded": "2000",
  "market_cap": 20834.445312,
  "pe_ratio": 53.438522,
  "forward_pe": 76.49856,
  "eps": 5.54,
  "revenue": 2198.899968,
  "profit_margin": 0.18291001,
  "debt_to_equity": 131.405,
  "return_on_equity": 0.37917998,
  "dividend_yield": null,
  "current_price": 296.0494079589844,
  "year_high": 329.3299865722656,
  "year_low": 173.0,
  "price_change_1d": -0.15534106487828375,
  "price_change_1w": -1.3135712535981425,
  "price_change_1m": -6.656134272723572,
  "description": "Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help re",
  "website": "https://www.insulet.com",
  "employees": 3900,
  "exchange": "NMS",
  "currency": "USD",
  "analyst_target_price": 336.01334,
  "recommendation": 1.56,
  "number_of_analysts": 24,
  "earnings_history": [],
  "analyst_data": {
    "target_high": 380.0,
    "target_low": 260.0,
    "target_mean": 336.01334,
    "target_median": 334.0
  },
  "last_updated": "2025-07-09T11:23:36.512568",
  "data_quality": {
    "has_financial_data": true,
    "has_earnings_data": false,
    "has_analyst_data": true,
    "completeness_score": 0.6666666666666666
  }
}